Mitomycin C as an Adjuvant in Resected Gastric Cancer

Publisher Website
Google Scholar
Abstract
As a result of previous experience with mitomycin C at high discontinuous doses in advanced gastric cancer, its role as an adjuvant for locally advanced cases after surgical complete resection was studied. Results from 70 evaluable patients are presented. Patients were allocated randomly to receive mitomycin C, 20 mg/m2 i.v. direct once every 6 wk, 4 courses, or a placebo. After a follow-up period of 250 wk, 7 treated patients and 23 controls relapsed (P < 0.001). Toxicity was moderate and controllable by symptomatic measures. This investigation is considered a positive contribution in the field of adjuvant therapy of gastric cancer.